Sanacute

Sanacute is a clinical-stage biotechnology company focused on developing novel therapies for acute organ injuries, with a primary emphasis on Acute Kidney Injury (AKI). The company's lead program, SN-001, is a small molecule inhibitor of the p53 protein designed to prevent cell death and inflammation in the kidneys following ischemic or toxic insults. Founded by experts in the field of renal medicine and p53 biology, Sanacute aims to address the significant unmet medical need in patients undergoing major surgeries or organ transplants who are at high risk for renal complications. The company's approach leverages the protective effects of transient p53 inhibition to preserve organ function and improve patient outcomes in critical care settings.